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Background: Contrast-induced nephropathy (CIN) is a well-recognized complication of coro-
nary angiography that is associated with poor outcomes. Several small randomized controlled
trials (RCTs) have recently shown that in patients with chronic kidney disease (CKD),
furosemide-induced forced diuresis with matched hydration using the RenalGuard system can
prevent its occurrence. However, individual studies have been underpowered and thus cannot
show significant differences in major clinical endpoints.
Hypothesis: Forced diuresis with matched hydration using the RenalGuard system improves
clinical outcomes in patients undergoing coronary angiography.
Methods: Scientific databases and websites were searched for relevant RCTs. The pooled risk
ratios were calculated using random-effects models. The primary endpoint was CIN, and the
secondary endpoints were major adverse clinical events (MACEs) and the need for renal
replacement therapy.
Results: Data from 3 trials including 586 patients were analyzed. High-volume forced diuresis
with matched hydration using the RenalGuard system decreased risk of CIN by 60% (risk ratio:
0.40, 95% confidence interval: 0.25 to 0.65, P < 0.001), MACE rate by 59%, and the need for
renal replacement therapy by 78%, compared with the standard of care.
Conclusions: In patients with CKD undergoing coronary angiography, high-volume forced
diuresis with matched hydration using the RenalGuard system significantly reduces the risk of
CIN, MACE rate, and the need for renal replacement therapy. Larger RCTs with sufficient
power are needed to confirm these findings.
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1 | INTRODUCTION
Acute kidney injury (AKI) is a well-recognized complication of coro-
nary angiography that is associated with greater risk of in-hospital
mortality and poor long-term outcomes.1 Contrast-induced
(CI) nephropathy (CIN) is the leading cause of AKI in these patients.2,3
Several therapies for CIN prevention have been investigated, includ-
ing the use of statins, bicarbonate, N-acetylcysteine (NAC), ascorbic
acid, adenosine antagonists, and vasodilators, but none have been
shown to consistently decrease the risk of CIN.4,5 Thus, a new
therapy to prevent CIN is critically needed. Recently, several small
randomized controlled trials (RCTs) and prospective studies have
shown that in patients with chronic kidney disease (CKD),
furosemide-induced high-volume forced diuresis with matched hydra-
tion using the RenalGuard system (RenalGuard Solutions, Inc.,
Milford, MA) can prevent CIN.6–9 However, some critiques are skep-
tical of these findings; they describe the results as simple changes in
biomarker (creatinine) levels because individual studies do not have
enough power to show significant differences in hard clinical end-
points such as renal replacement therapy (RRT) or major adverse
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clinical events (MACEs).10 This prompted us to perform a comprehen-
sive meta-analysis of the RCTs.
2 | METHODS
2.1 | Data selection and extraction
This meta-analysis was performed according to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.11 We performed a systematic search of PubMed, Google
Scholar, and http://www.clinicaltrials.gov and cross-referenced rele-
vant articles using various combinations of keywords such as “coro-
nary angiography,” “coronary intervention,” “contrast-induced
nephropathy,” “forced diuresis,” and “RenalGuard” for eligible pub-
lished studies. In addition, abstracts from major international cardiol-
ogy scientific meetings were reviewed. Data were collected by
2 independent investigators, and disagreements were resolved by
consensus. Trials were included if individuals undergoing coronary
angiography were enrolled and randomly assigned to either high-
volume forced diuresis with matched hydration using the RenalGuard
system or placebo. The potential risk of bias of RCTs was appraised
according to the Cochrane Collaboration guidelines (random
sequence generation and random allocation; allocation concealment;
blinding of participants, personnel, and outcome assessors; incom-
plete outcome data; and selective outcome reporting bias).12
2.2 | Outcomes
The primary endpoint was CIN. The secondary endpoints were
MACEs and the need for RRT. Study definitions were used for the
outcome data (see Supporting Information, Table S1, in the online
version of this article). We used the longest follow-up data for the
clinical outcomes.
2.3 | Statistical analysis
Traditional pairwise meta-analysis was performed using the Compre-
hensive Meta-Analysis system, version 3 (Comprehensive Meta-Anal-
ysis; Biostat Inc., Englewood, NJ). For discrete variables, pooled risk
ratios (RRs) were calculated using a random-effects model. For con-
tinuous variables, we summarized the data as the weighted mean dif-
ference and its 95% confidence interval (CI). We evaluated the
presence of heterogeneity across trials using the Cochran Q test and
the Higgins I2 test.13 When heterogeneity was discovered, a sensitiv-
ity analysis was performed by excluding 1 study at a time and evalu-
ating the impact on the summary results.14 Publication bias was not
assessed because the number of included trials (<10) was inadequate
to properly assess a funnel plot or to use more advanced regression-
based assessments.15
3 | RESULTS
3.1 | Study selection and patient population
Three RCTs that included 586 patients met the inclusion criteria.7–9
The search flow diagram is shown in the Supporting Information,
Figure S1, in the online version of this article. The bias assessment
for each RCT is shown in the Supporting Information, Figure S2, in
the online version of this article.
The Table 1 describes the characteristics of each individual trial,
all of which enrolled patients who underwent diagnostic coronary
angiography as well as intervention. (Inclusion and exclusion criteria
of each study are described in the Supporting Information, Table S2,
in the online version of this article.) The contrast volume was not dif-
ferent between the RenalGuard group and controls (weighted mean
difference: 6.0 mL, 95% CI: −15.4 to 27.4 mL, P = 0.584; see Sup-
porting Information, Figure S3, in the online version of this article).
Among controls, all patients received isotonic intravenous hydration.
Additional agents (eg, ascorbic acid, NAC, sodium bicarbonate) were
allowed based on the standard of care at the participating institution.
Comprehensive details of the various hydration protocols for both
the RenalGuard and control groups are described in the Supporting
Information, Table S3, in the online version of this article.
3.2 | Clinical outcomes
In patients undergoing coronary angiography, high-volume forced
diuresis with matched hydration using the RenalGuard system
TABLE 1 Characteristics of included trials
Characteristics
REMEDIAL II, 2011 MYTHOS, 2012 AKIGUARD, 2015
RenalGuard Control RenalGuard Control RenalGuard Control
N 146 146 87 83 59 65
Age, y 76  8 75  9 73  7 74  8 76  9 75  8
Baseline eGFR, mL/min/1.73 m2 32  9 32  7 38  11 41  10 42  11 45  13
Baseline sCr, mg/dL 1.80 (1.15–4.78)a 1.79 (1.15–3.85) 1.8  0.6 1.7  0.5 1.54  0.43 1.42  0.41
Baseline LVEF, % 46  11 48  10 51  13 52  13 53  10 50  14
DM, % 69 71 44 35 37 34
Contrast volume, mL 135  76 145  79 181  104 158  109 172  93 157  73
Abbreviations: AKIGUARD, Acute Kidney Injury Guarding Device; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IQR, interquartile
range; LVEF, left ventricular ejection fraction; MYTHOS, Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast-
Induced Nephropathy Prevention; REMEDIAL II, Renal Insufficiency After Contrast Media Administration Trial II; sCr, serum creatinine; SD, standard devi-
ation. Data are presented as mean  SD unless otherwise specified.
a Median (IQR).
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decreased the risk of CIN by 60% (RR: 0.40, 95% CI: 0.25 to 0.65,
P < 0.001) compared with the standard of care (Figure 1, A). The
RenalGuard system also decreased the MACE rate (RR: 0.41, 95% CI:
0.21 to 0.80, P = 0.010; Figure, B) and the need for RRT (RR: 0.22,
95% CI: 0.05 to 0.88, P = 0.032; Figure, C). No significant between-
trial heterogeneity for CIN (Q: 2.18, degrees of freedom [df]:
2, P = 0.336, I2 = 8.3), MACE (Q: 3.61, df: 2, P = 0.164, I2 = 44.7), or
the need for RRT (Q: 0.17, df: 2, P = 0.919, I2 = 0) was found.
Finally, no electrolyte-related complications resulted from the
use of the RenalGuard protocol.
4 | DISCUSSION
In this meta-analyses of RCTs, we compared furosemide-induced
forced diuresis with matched hydration using the RenalGuard system
with the standard of care. We found that in patients with CKD
undergoing coronary angiography, the RenalGuard system decreased
the risk of CIN by 60%. It also decreased the MACE rate by 59% and
the need for RRT by 78%.
AKI is a well-recognized complication of coronary angiography
that is associated with significantly higher risk of in-hospital mortality
and 1-year mortality, even in patients who do not need dialysis.1 In
these patients, CIN is a leading cause of AKI.2,3 The Mehran risk
score has been traditionally used to predict CI-AKI.2 However, it has
been suggested that several inflammatory markers—including white
blood cell count, neutrophil count, C-reactive protein, big endothelin-
1, and urine neutrophil gelatinase-associated lipocalin—are also
important predictors of CI-AKI.16,17 In addition, fragmented QRS
complex on 12-lead electrocardiography has also been shown to be
an independent predictor of postprocedural CIN in patients undergo-
ing primary percutaneous coronary intervention.18
Several therapies have been investigated for CIN prevention,
including the use of anti-inflammatory agents (statins), vasodilators
(calcium channel blockers, dopamine, fenoldopam, captopril, prostacy-
clin analogs, endothelin antagonists, L-arginine, and atrial natriuretic
peptide), adenosine antagonists (theophylline and aminophylline),
antioxidants (NAC, ascorbic acid, and sodium bicarbonate), anti-
ischemic agents (trimetazidine), remote ischemic preconditioning, and
RRT (prophylactic hemofiltration or hemodialysis).4,5,19 However, thus
far, the only strategies clearly shown to reduce the risk of CI-AKI are
hydration and minimizing the amount of contrast medium.4,5 Thus,
the search for new strategies that might be effective against CIN
continues.
Recently, a novel strategy to achieve a high urine output through
forced diuresis while maintaining euvolemia has been developed
using the RenalGuard system.20 A possible mechanism by which high
urine output through forced diuresis decreases the risk of CIN is by
limiting the contrast-nephron exposure time through acceleration of
tubule and collecting duct flow, reducing sledging and precipitation of
contrast material, clearing the contrast from the kidney before signifi-
cant damage occurs.7,8,20 However, previous studies of forced diure-
sis using mannitol or furosemide have generally shown harmful
effects.21 Those results were thought to be resultant of a failure to
maintain euvolemia resulting in the activation of the renin-
angiotensin system, leading to renal vasoconstriction.7,8,20 To over-
come this limitation, the RenalGuard system was developed, adjusting
the infusion rate second-by-second in response to changes in urine
output, thus preventing a net loss or gain of fluid from the body.
Basically, RenalGuard is a closed-loop fluid-management system in
which a urinary collection bag (which interfaces with a standard Foley
catheter) is hung on a digital scale, which in turn drives a high-volume
fluid pump.22 Each drop of urine entering the collection bag results in
an equal volume of saline infused back into the patient.22
The first human study using the RenalGuard system was reported
in 2009. It showed the safety of this device in 23 patients.23 Since
then, several RCTs and prospective studies have shown its efficacy in
patients with CKD undergoing diagnostic coronary angiography as
well as coronary intervention.6–9 Recently, the RenalGuard system
has also been shown to be effective in preventing kidney injury in
high-risk patients undergoing transcatheter aortic valve replacement
FIGURE 1 Individual and pooled risk ratios for (A) CIN, (B) MACEs,
and (C) the need for RRT. The risk ratio estimate of each study is
marked with a square. The size of the square represents the weight
that the corresponding study exerts in the meta-analysis; the larger
the square, the greater the study contribution to the overall estimate.
Diamond indicates overall summary estimate for the analysis (width of
the diamond represents the 95% CI). Abbreviations: AKIGUARD,
Acute Kidney Injury Guarding Device; CI, confidence interval; CIN,
contrast-induced nephropathy; df, degrees of freedom; MACE, major
adverse clinical events; MYTHOS, Induced Diuresis With Matched
Hydration Compared to Standard Hydration for Contrast-Induced
Nephropathy Prevention; REMEDIAL II, Renal Insufficiency After
Contrast Media Administration Trial II; RRT, renal replacement therapy
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(TAVR).24 Consistent with RCTs, several observational studies using
real-world populations have demonstrated the efficacy of this system.
In a study by Chorin, 150 patients undergoing coronary angiography,
angioplasty, or TAVR who were considered to be at high risk for CIN
received forced diuresis with matched hydration and exhibited a sig-
nificant decrease in their incidence of AKI.25 In addition, Briguori and
colleagues, using the RenalGuard system, demonstrated that a mean
intraprocedural urine flow rate of ≥450 mL/h is effective at prevent-
ing AKI in high-risk patients.26 Similarly, Visconti and colleagues
showed that the RenalGuard system was effective at preventing AKI
in 48 patients with CKD undergoing TAVR.27 Recently, a report from
the UK registry suggested that the RenalGuard system can signifi-
cantly reduce CIN in high-risk patients undergoing complex percuta-
neous coronary intervention.28
Our meta-analysis of RCTs showed that it decreases rates of CIN
and MACE and the need for RRT. Consistent with our findings, a
recent meta-analysis also showed that forced diuresis with matched
hydration using the RenalGuard system reduced the incidence of CIN
in high-risk patients undergoing coronary angiography.29 However,
their primary outcome was the incidence of CIN; therefore, no data
about the MACE rate were reported. One critique of these findings
may be that they are due to simple changes in biomarkers (creati-
nine), as no improvement in hard clinical endpoints was reported.10
Our meta-analysis showed that this protocol not only decreases the
risk of CIN but also decreases the rate of MACE.
RenalGuard is approved for sale in Europe and certain countries
around the world. The CIN-RG (Evaluation of RenalGuard System to
Reduce the Incidence of Contrast-Induced Nephropathy in At-Risk
Patients) RenalGuard pivotal study (NCT01456013) is underway in
the United States to support a planned premarket approval filing with
the U.S. Food and Drug Administration.
4.1 | Study limitations
This meta-analysis has several limitations. First, we did not have indi-
vidual participant data. Our statistical approach was performed at the
study level. Each study had its own protocol and definitions as well
as follow-up interval. Second, the type and duration of hydration
used for the control groups were variable across the studies. Finally,
a majority of these studies were single-center studies with small sam-
ple sizes, which potentially affects the generalizability of the findings.
5 | CONCLUSION
In patients with CKD undergoing coronary angiography, furosemide-
induced high-volume forced diuresis with matched isotonic intrave-
nous hydration using the RenalGuard system significantly reduces the
risk of CIN, MACE rate, and the need for RRT. Larger RCTs with suf-
ficient power are needed to confirm these findings.
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